Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 465 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: tumor peptide vaccine Clear all
Not listed Phase 1 Interventional

Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer

NCT02240537
View directory record Official record
Conditions
Acute Myelogenous Leukemia (AML), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Smoldering Multiple Myeloma (sMM)
Interventions
Sargramostim, BB-MPI-03, Montanide
Drug
Lead sponsor
Benovus Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Oct 13, 2026, 7:09 PM EDT
Not listed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00085397
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
autologous dendritic cell-tumor fusion vaccine, gp100 antigen, therapeutic autologous dendritic cells
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 9, 2009 · Synced Oct 13, 2026, 7:09 PM EDT
Active, not recruiting Phase 2 Interventional

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

NCT00338377
View directory record Official record
Conditions
Melanoma
Interventions
Dendritic Cell Immunization, Cyclophosphamide, Fludarabine, T-Cells, Interleukin-2, Mesna, Intrathecal T-Cells, Intrathecal Interleukin-2
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
1,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 13, 2026, 7:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Sequential Vaccinations in Prostate Cancer Patients

NCT00060528
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Recombinant Fowlpox-GM-CSF, Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM), Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM), Recombinant Human GM-CSF
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 13, 2026, 7:09 PM EDT
Recruiting Phase 2 Interventional Results available

A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer

NCT05242965
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Sargramostim, Computed Tomography, Biopsy, Biospecimen Collection
Biological · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
2
States / cities
Omaha, Nebraska • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 13, 2026, 7:09 PM EDT
Terminated Phase 1 Interventional

Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma

NCT00977145
View directory record Official record
Conditions
Melanoma
Interventions
A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1
Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 13, 2026, 7:09 PM EDT
Terminated Phase 2 Interventional

Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer

NCT01729884
View directory record Official record
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
HER-2/neu peptide vaccine
Biological
Lead sponsor
University of Washington
Other
Eligibility
19 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 13, 2026, 7:09 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00019994
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
MART-1 antigen, aldesleukin, gp100 antigen, incomplete Freund's adjuvant
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 13, 2026, 7:09 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00019929
View directory record Official record
Conditions
Lung Cancer
Interventions
mutant p53 peptide pulsed dendritic cell vaccine, adjuvant therapy
Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
2
States / cities
Bethesda, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 13, 2026, 7:09 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

NCT03127098
View directory record Official record
Conditions
Thyroid Cancer, Colon Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer
Interventions
ETBX-011, ALT-803
Biological
Lead sponsor
NantCell, Inc.
Industry
Eligibility
21 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 13, 2026, 7:09 PM EDT
Recruiting Phase 1 Interventional

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

NCT06218303
View directory record Official record
Conditions
Ductal Carcinoma in Situ
Interventions
MUC1 Peptide Vaccine, Hiltonol®, Aromatase Inhibitor, Selective estrogen receptor modulator (SERM)
Biological · Drug
Lead sponsor
Finn, Olivera, PhD
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 13, 2026, 7:09 PM EDT
Terminated Phase 1 Interventional

Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod

NCT01795313
View directory record Official record
Conditions
Ependymoma
Interventions
HLA-A2 restricted synthetic tumor antigen, Imiquimod, enzyme-linked immunosorbent assay, flow cytometry, immunohistochemistry staining method, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
James Felker
Other
Eligibility
12 Months to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 13, 2026, 7:09 PM EDT
Completed Phase 2 Interventional

Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer

NCT00445523
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
TroVax® (Immunological Vaccine Therapy), Interferon-alpha
Biological · Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 13, 2026, 7:09 PM EDT
Completed Phase 1Phase 2 Interventional

Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer

NCT01580696
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer, Fallopian Cancer, Peritoneal Cancer
Interventions
E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster, Non-vaccine clinically matched control group, E39 peptide (500mcg)/GM-CSF vaccine plus E39 booster, E39 peptide (1000mcg)/GM-CSF vaccine plus E39 booster, E39 peptide (100mcg)/GM-CSF vaccine plus J65 booster, E39 peptide (500mcg)/GM-CSF vaccine plus J65 booster, E39 peptide (1000mcg)/GM-CSF vaccine plus J65 booster
Biological · Other
Lead sponsor
COL George Peoples, MD, FACS
Federal
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Annandale, Virginia
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Oct 13, 2026, 7:09 PM EDT
Not yet recruiting Phase 2 Interventional

Testing the SurVaxM Vaccine for Lung Cancer Prevention

NCT07169617
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Biospecimen Collection, Montanide ISA 51 VG, Questionnaire Administration, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Aurora, Colorado • Chicago, Illinois • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 13, 2026, 7:09 PM EDT
Recruiting Phase 1 Interventional

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

NCT05142189
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
BNT116, Cemiplimab, Docetaxel, Carboplatin, Paclitaxel, BNT316, anti-B7-H3 antibody conjugated to topoisomerase I inhibitor, anti-HER3 antibody conjugated to topoisomerase I inhibitor, Bispecific antibody for PD-L1 and VEGF-A, Osimertinib, ALK-inhibitor or RET-inhibitor
Biological · Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
6
States / cities
Lexington, Kentucky • Louisville, Kentucky • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 13, 2026, 7:09 PM EDT
Completed Phase 2 Interventional Results available

Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma

NCT00773097
View directory record Official record
Conditions
Risk for Colorectal Cancer
Interventions
MUC1 - Poly ICLC
Biological
Lead sponsor
Robert Schoen
Other
Eligibility
40 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 13, 2026, 7:09 PM EDT
Completed Phase 2 Interventional Results available

HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM

NCT00905060
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
HSPPC-96, Temozolomide, Standard Surgical Resection
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
9
States / cities
San Francisco, California • Miami, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 13, 2026, 7:09 PM EDT
Completed Phase 1 Interventional

Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma

NCT00002748
View directory record Official record
Conditions
Neuroblastoma
Interventions
gene-modified tumor cell vaccine therapy, interleukin-2 gene
Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2007
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Oct 13, 2026, 7:09 PM EDT
Recruiting Phase 1 Interventional

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

NCT04943848
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions
rHSC-DIPGVax, Balstilimab, Zalifrelimab
Biological · Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
12 Months to 18 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Orange, California • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 13, 2026, 7:09 PM EDT
Completed Phase 1 Interventional

Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00091338
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, recombinant interleukin-7
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 13, 2026, 7:09 PM EDT
Completed Phase 2 Interventional

Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase

NCT00001685
View directory record Official record
Conditions
Melanoma, Neoplasm Metastasis
Interventions
Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 13, 2026, 7:09 PM EDT
Completed Phase 2 Interventional Results available

Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease

NCT00267085
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Minimal Residual Disease
Interventions
Synthetic Tumor-Specific Breakpoint Peptide Vaccine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 13, 2026, 7:09 PM EDT
Completed Phase 1 Interventional

An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer

NCT00054899
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Neoplasm
Interventions
EP2101
Biological
Lead sponsor
Epimmune
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
8
States / cities
Los Angeles, California • Orlando, Florida • Albany, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2010 · Synced Oct 13, 2026, 7:09 PM EDT